Sertindole : a review of its use in schizophrenia.

Article Details

Citation
Copy to clipboard

Murdoch D, Keating GM

Sertindole : a review of its use in schizophrenia.

CNS Drugs. 2006;20(3):233-55.

PubMed ID
16529528 [ View in PubMed
]
Abstract

Oral sertindole (Serdolect) is an atypical antipsychotic approved in the EU for once-daily use in patients with schizophrenia who are intolerant to at least one other antipsychotic agent. Extensive data from post-marketing studies do not indicate an excess of overall mortality with sertindole. Sertindole is at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS). Thus, sertindole is a useful option in the treatment of patients with schizophrenia.

DrugBank Data that Cites this Article

Drugs